Worse outcomes linked to newer corneal transplant techniques

Article

A study recently published in Ophthalmology found that newer lamellar techniques have worse survival and visual outcomes than penetrating keratoplasties.

A study recently published in Ophthalmology found that newer lamellar techniques have worse survival and visual outcomes than penetrating keratoplasties.

The study, conducted by the Australian Corneal Graft Registry, looked at 13,920 penetrating keratoplasties, 858 deep anterior lamellar keratoplasties (DALKs), and 2287 endokeratoplasties performed between January 1996 and February 2013 from long-standing national corneal transplantation register. Researchers used Kaplan-Meier functions to assess graft survival and surgeon experience, the Pearson chi-square test to compare visual acuities, and linear regression to examine learning curves.

The investigators found that from 1996 to 2006, the number of corneal grafts remained stable (mean 926), but the number increased over the course of the next six years, reaching 1,482 in 2012, revealing a need for 264 additional corneal donors throughout Australia. According to the study, this increase in procedures correlates with a shift in practice, with surgeons performing an increasing number of DALKs, endothelial grafts, and pseudophakic bullous keratopathy after 2006 and a declining number of penetrating grafts.

However, when researchers looked at outcomes, they found there was little benefit with the newer techniques when the procedures were matched by era and indication. Penetrating grafts had significantly better survival and visual outcomes compared with DALKs performed for the same indication during the same period.

Endokeratoplasties had significantly worse survival than penetrating grafts performed for the same indication during the same time. Compared with penetrating grafts, endokeratoplasties had significantly worse visual outcomes when performed for Fuchs' dystrophy (P < .001). However, they had significantly better visual outcomes when performed for pseudophakic bullous keratopathy.

Surgeons with more than 100 registered keratoplasties had better survival of endokeratoplasties compared to less-experienced surgeons. However, keratoplasty failure occurred even after 100 grafts among experienced, high-volume surgeons.

“The new procedures of lamellar keratoplasty that have evolved over the past two decades have been adopted enthusiastically by corneal surgeons worldwide,” write the study’s authors. “Although outcomes have been promoted as being significantly better than those of the well-established alternative of penetrating keratoplasty, the evidence for this claim is unconvincing outside of single-center studies.”

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.